Colinz Laboratories Limited
COLINZ.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$183.97M
Close$
$71.46
2.1% upside
Current Fair Value
2.1% upsideUndervalued by 2.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $183.97 Million |
|---|---|
| Enterprise Value | $183.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.04 |
| Beta | -0.09 |
| Outstanding Shares | 2,519,100 |
Return
| Return on Equity | 27.84% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 6.58 |
|---|---|
| PEG | 0.34 |
| Price to Sales | 3.04 |
| Price to Book Ratio | 1.79 |
| Enterprise Value to Revenue | 3.17 |
| Enterprise Value to EBIT | 5.58 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Colinz Laboratories Limited
62 employees
CEO: Narayanan Kutty Menon Colinz Laboratories Ltd. specializes in producing a diverse range of pharmaceutical formulations, available in various dosage forms such as tablets, capsules, granules, oral liquids, injectables, ointments, and creams. The company's offe...